Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) | BeOne Medicines

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström’s Macroglobulinemia (WM)

Beigene Study ID

BGB-3111-210

ClinicalTrials.gov ID

NCT03332173

China Drug Trials ID

CTR20170208

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan